Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors
A Phase 1 Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-MIF Antibody in Subjects With Malignant Solid Tumors
Sponsor: Baxalta now part of Shire
Listed as NCT01765790, this PHASE1 trial focuses on Malignant Solid Tumors and Metastatic Adenocarcinoma of the Colon or Rectum and remains completed. Sponsored by Baxalta now part of Shire, it has been updated 10 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jun 2021 [monthly]
Completed PHASE1
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 5 earlier versions
-
Jun 2019 — Sep 2019 [monthly]
Completed PHASE1
-
Jun 2018 — Jun 2019 [monthly]
Completed PHASE1
-
Nov 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Feb 2017 — Nov 2017 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Jun 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baxalta now part of Shire
For direct contact, visit the study record on ClinicalTrials.gov .